This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Buy, Sell or Hold HOLX Stock Ahead of Q4 Earnings?
by Moumi Mondal
Hologic's upcoming fourth-quarter fiscal 2024 financial report is expected to reflect strength in core franchises.
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
by Zacks Equity Research
BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MDT Stock Trades Near 52-Week High: Is it a Smart Buy Now?
by Urmimala Biswas
The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
by Zacks Equity Research
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
Top Analyst Reports for NVIDIA, American Express & Wells Fargo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), American Express Company (AXP) and Wells Fargo & Company (WFC), as well as two micro-cap stocks Elite Pharmaceuticals, Inc. (ELTP) and PrimeEnergy Resources Corporation (PNRG).
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
BD Stock Rises as Neopak XtraFlow Syringe Expands in Biologics
by Zacks Equity Research
BDX launches the Neopak XtraFlow Glass Prefillable Syringe, enhancing drug delivery for biologics and expanding capacity with new high-volume production lines.
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
by Urmimala Biswas
MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Becton Dickinson (BDX) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?
by Moumi Mondal
Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment perspective.
BD Stock Falls After Acquisition of Edwards' Critical Care Group
by Zacks Equity Research
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
EW Stock Dips Following the Divestiture of Critical Care Wing
by Zacks Equity Research
Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?
by Urmimala Biswas
Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.
Hologic (HOLX) Q3 Results Review: How to Play the Stock Now?
by Moumi Mondal
Hologic's (HOLX) performance in the third quarter of fiscal 2024 marks a return to growth, along with revenues and earnings beating estimates. Read on to find out what else the stock holds.